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“probiotic strains should be selected for products based on evidence of their phenotype rather
than simply relying on the popularity of their species name.”
In recent years there has been a rapid rise in interest for the application of probiotic supplements to act
as mediators in health and disease. This appeal is predominantly due to ever-increasing evidence of the
interaction of the microbiota and pathophysiological processes of disease within the human host. This
narrative review considers the current landscape of the probiotic industry and its research, and discusses
current pitfalls in the lack of translation from laboratory science to clinical application. Future considera-
tions into how industry and academia must adapt probiotic research to maximize success are suggested,
includingmore targeted application of probiotic strains dependent on individual capabilities as well as ap-
plication of multiple advanced analytical technologies to further understand and accelerate microbiome
science.
Lay abstract: The global market for probiotic supplements is continually expanding. Despite the pub-
lic perception of benefits provided by probiotics, the evidence to conclusively link probiotic strains to
improved characteristics of health or disease is lacking. This is owing, in part, to the lack of large-scale
research trials, but also to the insufficient understanding of the interactions occurring within the human
system following supplementation. More in-depth research into individual probiotic strains, combined
with the application of multiple advanced measurement techniques will provide a future direction for
probiotic research and, in turn, aim to provide useful data to translate into routine healthcare practice.
First draft submitted: 11 January 2019; Accepted for publication: 20 March 2019; Published online:
3 May 2019
Keywords: disease • health • metabolomics • metagenomics • metatranscriptomics • microbiome • probiotics •
proteomics
The symbiotic relationship between the human host and its bacterial residents has gained extensive research
interest in recent years. These bacteria are predominately present within the gastrointestinal system, and along
with their collective genomes, are known as the gut microbiome [1]. Increasing evidence suggests that the gut
microbiome plays an important role in human host homeostasis, health and disease (Figure 1). Positive effects
of gut bacteria have been largely associated with gastrointestinal function, appetite and immune response [2–5].
However, a number of negative effects have been reported across a wide-range of diseases and health conditions,
with many associations based on a shift in gut bacterial content and the interaction of metabolites produced
following bacterial metabolism of dietary components [6–13]. For these reasons, there has been an invested interest
in the application of probiotic supplements as both potential promoters of good health, together with therapeutic
modulators of disease development and progression. This narrative review article looks to address the current
knowledge and landscape of probiotic research and provide a brief overview to existing applications in health and
disease, as well as discuss the potential future directions of probiotic investigations and subsequent translation to
the global industry and market.
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Figure 1. A diagrammatic overview of the positive and negative influence of gut bacteria represented across a
wide-range of health and disease conditions.
Lots of research, but still no health claim
The global probiotic market is worth approximately $15 billion USD per year and is growing at an estimated
annual rate of 7% [14]. In recent years, there has been a flourish of interest in research in the microbiome and
probiotics. A literature search for probiotics carried out today will return over 19,000 results including some of the
most widely read and reputable scientific publications. In particular, a MEDLINE/PubMed search for literature
that matches the terms ‘probiotics’ alongside ‘health’ OR ‘disease’ will list almost 10,000 results and demonstrates
a rapid rise in research publications with an approximate threefold annual increase in the previous decade and
34-fold increase since 1998 (Figure 2). These include clinical trials, reviews and meta-analyses focusing on clinical
presentations as diverse as atopic dermatitis to Clostridium difficile-associated diarrhea (CDAD) [15–17], to anxiety
and depression [18–20]. Nevertheless, this extensive body of clinical research has not translated into clearly defined
health or medicinal claims for probiotics.
Despite mounting evidence for the use of probiotics in a range of conditions, relatively few strains are commercially
available and probiotics are seldom used in routine clinical practice [14]. The European Food Safety Authority (EFSA)
has listed three main regulatory issues to be addressed when making a health claim. This has led to many health
claims for probiotics being rejected to date, and has even restricted the use of the term ‘probiotic’ as it is believed
that the name itself implies a health benefit. These regulatory issues include the requirement for the demonstrated
evidence of:
• Characterization of the probiotic product;
• Substantiation of the health benefit (i.e., demonstration that the biomarker in question contributes to the claimed
health benefit), and;
• Extrapolation to the general, healthy population.
Health claims must be specific and claims such as ‘strengthens the immune system’ are considered too vague by
EFSA [21]. Much research has gone into establishing an evidence base for probiotics having an impact on various
biomarkers. However, there is no established set of approved biomarkers which are correlated with (and validated
by) clinical endpoints [22]. EFSA requires claimed health effects to be demonstrated in at least two randomized,
placebo-controlled clinical trials, with a clearly demonstrated cause and effect relationship. It has been suggested
that poor study design, a lack of investment in research and development, and a lack of fundamental knowledge
about the biological mechanisms of action has led to ‘pilotitis’ – whereby small and diffused projects do not
create a sufficient evidence-base to obtain regulatory approval [14]. A clear example of this is found in a recent
systematic review of randomized controlled trials (RCTs) investigating probiotics in the management of irritable
bowel syndrome (IBS). From the 35 RCTs reviewed, of which only three had at least 100 participants, the authors
concluded that approximately 75% were pilot studies [23]. Adequately powered Phase III probiotic clinical trials are
required to provide the level of evidence that will generate confidence in product efficacy to clinicians and health
authorities.
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Figure 2. Annual (top) and cumulative (bottom) trend of published research manuscripts indexed on
MEDLINE/PubMed matching the terms ‘probiotics’ AND (‘health’ OR ‘disease’) [data refer to search conducted on 27
November 2018].
Diversity, dysbiosis & strain specificity
The Human Microbiome Project (HMP1), a National Institute of Health-funded project based on 250 healthy
volunteers, discovered that the human microbiome is comprised of between 3500 and 35,000 species; inferred
from operational taxonomic units [24]. The total number of bacterial cells present within the human body has been
estimated at 1013, a value similar to that of the number of host cells [25]. The human body thus accommodates
a very diverse and abundant collection of microorganisms; however, there is considerable variability in diversity
between body sites. For example, oral and colonic sites have bacteria highest in quantity, with lowest abundances
measured in the vagina [24]. High gastrointestinal microbial diversity is found in hunter-gatherer populations, such
as the Hadza in Tanzania [26] and the Yanomami in Brazil [27], which likely represent our ancestral human state.
These dwindling cultural groups show evidence of good health in contrast to modern Westernized populations
colonized by a far less diverse microbiota [28]. Low diversity in the lower GI tract (GIT) is associated with a range
of conditions including obesity, Crohn’s disease, IBS and colorectal cancer [29]. However, high diversity is not a
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universal marker of a healthy microbiome, given that such a state in the vagina, for instance, defines bacterial
vaginosis [30]; the most common cause of vaginitis.
Diversity frequently appears in definitions of dysbiosis; a commonly used term in this field referring to an
‘abnormal’ microbiome. Dysbiosis, which is frequently ill-defined in many publications, appears to cover not only
changes in diversity, but also loss in keystone taxa (important species that drive community composition and
function), proliferation of pathogens, and changes in metabolic capacity; the latter adding a functional component
to the former structural elements [31]. Dysbiosis is not easily defined owing to the fact that eubiosis, a healthy or
homeostatic microbiome, is such a heterogeneous state [32]. Microbiome profiling studies have identified unique
interpersonal taxonomical patterns, even among twins [33], however the existence of a stable core of functions and
thus genes (the microbiome core) has been substantiated [32]. What is yet to be clearly defined is what constitutes
a ‘healthy’ gut microbiota and exactly how different strains and species of gut bacteria affect their host. Interstudy
variations in strains, doses and treatment duration make comparing studies and reaching a general consensus
difficult.
The genetic difference between one probiotic bacterium and the next may be larger than the difference between a
man and a goldfish [34]; as such the function of one strain cannot always be extrapolated to another. This is referred
to as strain specificity, and is clearly demonstrated in the study by Douillard et al. [35] in which 100 strains of the
species Lactobacillus rhamnosus, obtained from both human and dairy sources, display very different characteristics
such as bile acid resistance, carbohydrate transport and metabolism, and production of mucus-binding pili. This
study lends weight to the fact that taxonomic profiling is an inadequate measure of functional capacity, and that
probiotic strains should be selected for products based on evidence of their phenotype rather than simply relying
on the popularity of their species name.
Multi-omics technologies to revolutionize & accelerate microbiome science
The microbiome and its influence on the human host is not solely dependent on the presence/absence and distribu-
tion of bacterial species but can be further understood through the independent and multifaceted investigation of
bacterial metabolic, proteomic and gene expression profiles. This is demonstrated through the investigation of two
phylogenetically distant bacterial groups, Lactobacilliales and Bifidobacteriales, that are commonly termed as ‘lactic
acid-producing bacteria’. The Lactobacillus genus is diverse, containing at least 12 separate phylogenetic groups
with more than 150 species isolated from the mammalian GIT [13]. However, the microbiota (the assemblage of
microorganisms present in a defined environment) consists of far more than just lactobacilli and bifidobacteria. The
identification of these bacterial systems and the analysis of their contribution to host biochemistry and physiology
has been accelerated through modern advanced analytical techniques that sit within ‘omics’ technologies and include
metataxonomics, metatranscriptomics, (meta)proteomics and metabolomics/metabanomics [1] (Figure 3).
The human gut microbiome is genetically diverse, expressing approximately 150-times more genes than the
human host [36]. Since it is agreed that the majority of the bacteria commonly identified in the microbiome cannot
be routinely cultured using traditional laboratory techniques (ca. 80% or greater) [37], we rely on high-throughput
sequencing approaches to gain a comprehensive insight into this complex microbial community [38]. Historically,
the most common DNA-based approach applied to interrogate the microbiome applies targeted amplification of
specific phylogenetic marker genes to make taxonomic inferences. This targeted approach is termed metataxonomics
and is most frequently achieved through PCR amplification of regions of the ribosomal rRNA 16S gene, which are
highly conserved across taxa [39]. Since this method only requires a sequence from a single gene, it represents a cost-
effective and widely utilized procedure for identifying species diversity in the gut microbiome. However, care should
be exercised when targeting a precise region of the 16S gene as this has been shown to have an influence on the type
of bacteria queried and can introduce experimental bias [40]. Data outcomes resulting from this method of analysis
are clustered into operational taxonomic units based on their similarity to other sequences in the community [41].
Taxonomic classifications are then assigned using reference databases such as the Ribosomal Database Project (RDP),
Greengenes, Open Tree of Life Taxonomy (OTT) and SILVA NCBI to define taxonomy [42]. A metataxonomic
approach was ubiquitously applied in the initial phase of HMP1, which characterized the microbiomes of healthy
individuals across five anatomical locations [43].
Rather than amplifying a specific phylogenetic marker, metagenomics utilizes high-throughput sequencing to
provide a non-targeted analysis of all DNA extracted [1]. DNA is first isolated, then randomly sheared using a
shotgun approach, sequenced and analyzed to generate a full genomic profile of the microbiome [44]. Overlapping
sequences of DNA are assembled into longer genomic sequence contigs that are subsequently annotated against
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Figure 3. Overview of multi-omics technologies and associated analytical techniques.
GC: Gas chromatography; HPLC: High-performance liquid chromatography; LC-MS: Liquid chromatography–mass spectrometry; MALDI:
Matrix-assisted laser desorption ionization; MS: Mass spectrometry; NGS: Next-generation sequencing; NMR = nuclear magnetic resonance.
existing databases using complex algorithms for phylogenetic and functional analysis, such as MG-RAST, IMG/M
and EBI Metagenomics [45]. Metagenomics was first described in 1998 by Handelsman & Rodon and has since
provided an unparalleled insight into the functional genetic profiles of microbial communities [46]. The approach
enables the analysis of fundamental microbial pathways associated with the gut microbiome, as well as genes
associated with antibiotic resistance and the co-evolution between microbiota and host. To date, several sequencing
platforms have been applied to metagenomics ranging from traditional Sanger sequencing to high-throughput next-
generation sequencing using 454/Roche and Illumina/Solexa systems, with each method presenting advantages
and disadvantages relating to insert size, read length, depth, sequence accuracy, usability and cost [47]. For a
comprehensive and critical evaluation of these sequencing platforms we recommend the review by Kuczynski
et al. [41].
The traditional genomic approaches previously described the profile of total cumulative DNA present in a sample.
This, however, tells us little about epigenetic factors, such as which genes are expressed, which are suppressed and
in what proportions. To answer these questions, we can apply metatranscriptomics. This approach analyses mRNA
expression in the microbiome via the high-throughput sequencing of meta-cDNA [48]. By specifically analyzing
genes that are actively expressed in the microbiome it becomes possible to compile a functional picture of meta-
genomic activity. Consequently, this form of analysis can provide adjunct information to existing metagenomics data
and makes it a powerful tool for distinguishing dynamic changes in gene expression resulting from environmental
factors that impact the microbiome, such as dietary changes [49]. Furthermore, outcomes from metatranscriptomic
analyses have the capacity to distinguish co-evolutionary developments, which are important in enhancing our
understanding of the symbiotic relationship between microbiome and host [50].
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Increasingly, meta-genomic analyses are being combined with complementary approaches including metapro-
teomics and metabolomics/metabonomics to provide a meta-omics analysis that yields insights that cannot be
obtained through a single method of analysis.
The biological system-wide collection of proteins carries the term proteome and was originally described as
‘the total protein complement of a genome’ [51]. This has led to an ever-increasing interest in the global study
of proteins and their interactions, with the term proteomics described as ‘the use of quantitative protein-level
measurements of gene expression to characterize biological processes (e.g., disease processes and drug effects) and
decipher the mechanisms of gene expression control’ [52]. In contemporary discovery proteomics, also known as
shotgun or bottom-up proteomics, proteins are cleaved into peptides using proteolytic enzymes and then analyzed
by liquid chromatography coupled to high-resolution mass spectrometry [53]. This provides a peptide map of the
analyzed sample that can then be stitched back together by specialist software to provide confident identification of
measured proteins through the detection and measurement of known unique peptide fragments [53]. Subsequently,
this affords the possibility of mapping the microbiota proteome, giving a functional overview of the proteins and
polypeptides produced by the microbiota. In recent years, a substantial body of evidence has accumulated which
suggests that certain surface-associated and extracellular products made by probiotic bacteria may be responsible
for some of their mechanism of action. It is thought that these bacterial components interact directly with the host’s
mucosa and include: exopolysaccharides, bacteriocins, lipoteichoic acids and surface-associated and extracellular
proteins [54].
The application of proteomics in probiotic research has mostly applied to the direct measurement of secreted
or membrane proteins linked directly to the bacterial strains [55–57], with less emphasis on their interaction and
subsequent impact on the total proteome of the host system – in other words, proteins present from the bacteria-
host interaction. Nonetheless, attempts have been made to understand the proteomic changes following probiotic
supplementation, with initial successes drawn from these analyses. For example, Reiff et al. [58] measured cecum
proteins following a supplementation protocol of a commercial multistrain probiotic to IL-10 knockout mice,
a model of inflammatory bowel disease (IBD), for 21 weeks. The data showed that 9 proteins increased and 2
decreased at a level greater than twofold, with a ninefold increase in measured LGALS2 that has previously been
demonstrated in vitro to contribute to epithelial would healing and suppression of activated T cells [59,60]. In
addition, decreases in measurements of REG3G were seen in mice with decreased IBD severity following probiotic
treatment compared with those which were administered a saline placebo. Similarly, in IBS an 8-week probiotic
supplementation (Lactobacillus acidophilus NCFM and Bifidobacterium lactis HN019) to animals demonstrated that
PPAR-γ signaling proteins were maintained at levels equivalent to nonsupplemented healthy controls, compared
with IBS-induced animals without supplementation that showed decreased PPAR-γ content [61]. Conversely, it has
also been demonstrated that probiotic supplementation exerts no impact on overall fecal proteome measurements
and variances are more reflected through personalized differences in microbiome content [62].
Although there are limited investigations assessing the impact on the global metaproteome following probiotic
supplementation, promising initial data point toward alterations in protein production that are related to health
and disease and warrants further study.
Metabolomics refers to the study of metabolites produced and released through biochemical pathways that can
be measured both systemically and at the cellular level and are an indication of the physiological state of the
organism or system [63]. Furthermore, the term metabonomics describes the measurement of metabolites that are
measured from a multi-organism system such as the human body and its incorporated microbiota [64,65]. The
collection of metabolites produced by these organisms is collectively referred to as the metabolome [65]. Although
microbiome-focused research has been performed on the global profiling of metabolites [66–68], the targeted analysis
of gut-mediated metabolites has received more research interest over recent years. For example, gut bacterial
metabolites have been shown to have mechanistic and associative effects on human health, with perhaps the most
well-documented being the gut-mediated metabolite of trimethylamine N-oxide, or more commonly known as
TMAO. TMAO is produced through gut bacterial metabolism of dietary-derived quaternary amine molecules
such as choline and L-carnitine [69,70]. Some bacteria possess the genetic code to cleave the trimethylamine (TMA)
group from these molecules and release it as a metabolic by-product, with CutC and CntAB the most common
genes required for the digestion of choline and L-carnitine, respectively [71]. The released TMA is then absorbed
through the gut wall into the portal vein and transported to the liver where it is converted by flavin-containing
monooxygenases (e.g., FMO3) through N-oxidation to TMAO [72] (Figure 4).
10.4155/fsoa-2019-0004 Future Sci. OA (2019) FSO391 future science group
Probiotics: current landscape & future horizons Review
TMA removed from choline
and L-carnitine by bacteria
TMA converted to TMAO in liver by
flavin monooxygenases (FMO3) and
released into circulation.
Choline
L-carnitine
TMAO TMAO
TMA
FMO3
TMA TMAO
TMA
N+
CH3
O-
O
H3C
CH3
OH
H3C
N
CH3
CH3
N
O
H3C CH3
CH3
Figure 4. A schematic drawing to demonstrate gut bacterial metabolism of dietary components choline and
L-carnitine into TMA which is subsequently converted to TMAO by liver flavin-containing monooxygenases
(e.g., FMO3). TMA: Trimethylamine; TMAO: Trimethylamine N-oxide.
TMAO has gained worldwide media coverage through its associations with multiple diseases, centered primarily
on cardiovascular disease. Elevated levels of TMAO have shown mechanistic effects in animal models through
acceleration of atherosclerotic plaque formation [70], worsening of pressure overload-induced heart failure [73] and
elevated fibrotic potential in renal tissue [74]. In addition to this, associations with increased circulating levels of
TMAO (measured in plasma and serum) have been demonstrated as biomarkers able to independently predict
the risk of adverse outcome in chronic and acute cardiac disease patients [75–78]. To this end, it is not surprising
that there have been efforts to reduce the accumulation of TMAO within the systemic circulation, with chemical
inhibitors of TMA-lyase activity shown to effectively reduce bacterial production of TMA [79,80]. This chemical
approach has yet to be translated to human patient cohorts, but efforts to reduce TMA/TMAO levels through
probiotic supplementation have been made albeit with mixed success [81–85]. The dosing of human participants
with commercially available probiotic products is unlikely to have a meaningful effect on TMAO production. A
more focused analysis of the mechanistic actions of particular bacterial strains and their metabolic capabilities is
required before any health claim benefits can be realized.
Potential probiotic (and prebiotic) approaches have further been identified with the view to the increased
production of certain metabolite by-products. For example, short-chain fatty acids (SCFAs, particularly acetate,
propionate and butyrate) are predominantly produced following the fermentation of dietary fiber and have shown
positive associations with the reduction in pathophysiological processes of disease [86]. Of note, Andrade-Oliveira
et al. [87] demonstrated that increased bioavailability of fecal and circulating acetate could be achieved through
probiotic supplementation of known acetate-producers Bifidobacterium adolescentis or B. longum. Subsequent
experiments in mice showed that the probiotic supplement ameliorated ischemia-induced renal tissue damage to
a similar degree as to when acetate was administered by chemical supplementation (200 mg/kg acetic acid in
PBS buffered to pH 7.4). Further, colocalization of the probiotic treatment was confirmed by the detection of
fluorescently labeled bacteria in the intestinal niche, albeit at a low occurrence. A high-fiber diet (which functions
as a prebiotic approach to increase SCFA production [88]) has also achieved positive therapeutic effects in kidney
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disease, with improvements in renal function and blood pressure coupled with decreased levels of inflammation,
oxidative stress and fibrosis [89].
Altogether, the impact of gut-mediated metabolites on the human biological system provides promising ap-
plications of probiotic supplementation combined with nutritional strategies to modulate bacterial metabolite
production and subsequently improve health and disease characteristics.
In isolation, all of the described omics-based investigations offer an abundance of data and potential information
on the workings of the microbiome to further characterize the complex nature of the microbiota-host interaction.
Increasingly, meta-genetic analyses are being combined with complementary approaches including metaproteomics
and metabolomics to provide a meta-omic analysis that yields insights that cannot be obtained through a single
method of analysis. The ability to combine these datasets to generate meta-omics investigations will provide
an improved understanding of the elaborate processes in place to elucidate the underlying biological basis and
mechanism of action of probiotics.
The biological basis & mechanisms of action of probiotics
The heterogeneous nature of the gut microbiota is mirrored in the varied mechanisms of action of different
microbial species. The biological effects of probiotics can be divided into several broad categories:
• Pathogen resistance: Probiotics are thought to maintain, or re-establish, host microbial homeostasis and corre-
spondingly reduce pathogenic invasion and colonization. If endogenous microbes are able to occupy all functional
niches, there is a reduced likelihood of pathogenic invasion and colonization in that ecosystem. Probiotics can
either occupy functional niches that are left open by the endogenous community (preventing opportunistic in-
fection) or they may directly alter the local environment through the secretion of SCFAs, lactic acid, bacteriocins
and reactive oxygen species to inhibit the growth of pathogenic organisms [90].
• Nutritional functionality: Certain species of the gut microbiota contribute to vitamin availability and production
of SCFAs. Vitamin K, vitamin B12, pyridoxine, biotin, folate, nicotinic acid and thiamine can all be produced
by gut micro-organisms [91]. Furthermore, butyrate is a major energy source for enterocytes and is involved in
the maintenance of the enteric mucosa [92].
• Immune functionality: Probiotics have been shown to have diverse effects on the immune system. Some probiotic
species can be categorized as immunostimulatory (i.e., pro-inflammatory) and are characterized by their ability
to induce IL-12 and natural killer (NK) cell immunity [93]. Other species are categorized as immunoregulatory
(i.e., anti-inflammatory) due to their ability to induce IL-10 and regulatory T cell pathways [94]. The overall
effect on the immune system is totally dependent upon the specific probiotic species or strain, with some acting
as pro-inflammatory and others as anti-inflammatory agents.
• Amelioration of contaminants: Certain probiotics can lower the risk from ingested hazardous compounds. For
example, Pedicococcus pentosaecus breaks down fumonisins, a group of mycotoxins produced from fungi, which
are found on a wide variety of crops [91].
• Xenobiotic and drug metabolism: Recent research has shown that the gut microbial metabolite p-cresol can reduce
the capacity of the liver to metabolize paracetamol due to competitive inhibition of hepatic sulfotransferases.
The role of the gut microbiota in drug and xenobiotic metabolism could have a profound impact on therapy
options for various conditions in the future [95]. Furthermore, there is increasing evidence to show that dietary
and environmental chemical pollutants can interfere with gut bacterial function (transcription, metabolism etc.)
and can consequently affect host health through inducing a pro-inflammatory response within the gut [96,97].
• Bile acid metabolism: Certain species of the gut microbiota – such as Bacteroides intestinalis – have been shown to
deconjugate and dehydrate primary bile acids to convert them into secondary bile acids [95]. Secondary bile acids
can inhibit Clostridium difficile spore germination and, therefore, suppress the vegetative growth of C. difficile [98].
Clinical probiotic research
Probiotics have been extensively studied in gastrointestinal diseases including: infectious gastroenteritis, antibiotic-
associated diarrhea (including CDAD), IBD and IBS [15,23,99,100]. A 2017 Cochrane review of 31 trials in the
prevention of CDAD concluded that probiotics achieved a risk reduction of 60% (number needed to treat to
benefit one person = 42 patients, 95% CI: 32–58) [16]. Based on this review, probiotics have been recommended
as ‘safe and effective when used in conjunction with antibiotics for the treatment of C. difficile’ in the National
Institute for Health and Care Excellence (NICE) Clinical Knowledge Summaries webpage [101]; a service that
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provides primary care practitioners with summaries of the current evidence base and practical guidance on best
practice in many common presentations. However, a 2018 review of Cochrane reviews concluded that probiotics,
in the management of IBD (both Crohn’s and ulcerative colitis), lack sufficient evidence to allow their benefits
to be determined and that more research is required [99]. Numerous probiotic products have been trialed in the
management of IBS, as described earlier, and the 2017 NICE clinical practice guidelines for IBS in adults found
good-quality evidence that combination (multi-strain) probiotics significantly improve global IBS symptoms, pain,
and bloating compared with placebo [102]. In support of this, the largest probiotic RCT to date in IBS (400 patients
in a randomized approach) found that a 14-strain probiotic significantly improved all these symptoms, and also
substantially increased quality of life [103].
Obesity, and its related metabolic diseases, are a burgeoning international problem for both health and healthcare
systems. The combined medical costs associated with treating obesity-related diseases are estimated to increase by
$48–66 billion per annum in the USA and by £1.9–2.0 billion per annum in the UK by 2030 [104]. Current
management of obesity with long-term medication or surgical intervention have been shown to be efficacious but
not without considerable side effects [105,106]. Probiotics, as an adjunct to healthy diet and lifestyle, may offer a
low-risk option for such patients. In a 2018 review of 15 probiotic RCTs in overweight or obese subjects, probiotics
achieved a significantly larger reduction in body weight and BMI compared with placebo; albeit with small effect
sizes [107]. Intriguingly, in the largest subsequent RCT to date, researchers identified that a heat-killed probiotic strain
(Bifidobacterium animalis subsp. lactis CECT 8145) lead to the most significant reductions in waist circumference
and waist to height ratio compared with placebo, thus suggesting that the beneficial effects might be obtained from
nonviable bacterial components [108].
The relationship between the gut microbiota and neuropsychiatric conditions is also proving to be a rapidly
evolving field of research. Referred to as the ‘gut-brain axis,’ this describes the bidirectional communication system
that exists between the GIT and the central nervous system, utilizing neurological, immunological and hormonal
signaling pathways [109]. Promising preclinical research has demonstrated that probiotic supplementation can
alter the gut microbiota to ameliorate anxiety-like behavior [18] and depressive-like behavior in mice [110]. Several
further rodent studies have shown that consumption of probiotics can prevent increases in certain stress hormones,
including ACTH, corticosterone and epinephrine via the hypothalamic-pituitary-adrenal axis [19]. Human clinical
trials examining the effect of probiotics on neuropsychiatric conditions are relatively small in number at present but a
recent systematic review provides an interesting perspective on the current evidence base for the effects of probiotics
on symptoms of depression and anxiety [19]. The clinical trials to date demonstrate an exciting – if somewhat
heterogenous – set of results that in many ways mirror other areas of probiotic research. In a 2016 randomized
placebo-controlled trial, Akkasheh et al. [111] demonstrated a significant reduction in depressive symptom scores
(as measured by the Beck’s Depression Inventory) following an 8-week period of probiotic supplementation with
Lactobacillus acidophilus, L. casei and Bifidobacterium bifidum. Furthermore, Rao and colleagues [112] conducted a
randomized placebo-controlled trial examining the effect of L. casei on anxiety symptoms in patients with chronic
fatigue syndrome. In this trial, it was observed that consumption of L. casei daily for 2 months led to a significant
decrease in anxiety symptoms among those taking the probiotic when compared with controls, further adding to
the evidence base. In a recent review, Romijn & Rucklidge [113] coined the term ‘psychobiotics’ to refer to probiotics
which produce a health benefit in patients suffering from psychiatric illness.
However, psychobiotics are not the only focus of probiotic research into the gut-brain axis. Epidemiological data
demonstrate an interesting correlation between migraine sufferers and gastrointestinal conditions, such as coeliac
disease and IBD [114]. In light of this, researchers investigated the effects of a multispecies probiotic supplement
on migraine patients [115]. The trial included individuals diagnosed with either episodic or chronic migraine (as
defined by the International Headache Society). Measured against placebo controls, individuals that received the
multispecies probiotic experienced a statistically and clinically significant reduction in frequency and severity of
migraine attacks, in addition to a reduction in weekly abortive drug usage. While the pathophysiology of migraine
is phenomenally complex and yet to be definitively characterized [116], this trial adds to the evidence base that
migraine is a multisystem condition, and provides a novel potential avenue for migraine prophylaxis.
Although gastrointestinal diseases have been the traditional focus in microbiome and probiotic research, the scope
has been dramatically broadened in recent years to include virtually every organ system in the body. Probiotics
have demonstrated efficacy in reducing blood urea levels in chronic renal failure [117], treating and preventing
atopic dermatitis [118,119], reducing transaminases and measures of fibrosis in non-alcoholic steatohepatitis [120],
improving dysphoria and depression [19], preventing antibiotic-associated diarrhea [15] and even treating symptoms
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of ophthalmological conditions such as vernal keratoconjunctivitis [121]. The research in many of these areas is in
its infancy, and there is a requirement to better understand the underlying mechanisms of action, in conjunction
with high-quality Phase III studies, if probiotics are to be integrated into widespread mainstream clinical practice.
Conclusion
The probiotics industry is an ever-growing entity with continual expansion of products being taken to market.
This has driven scientific research with the aspirations to uncover probiotic strains that provide conclusive evidence
of improvements in health and disease outcomes. These opportunistic endpoints have not currently been met,
evidenced by the fact that no certified health claims credited to probiotic products are currently in place. This is
likely owing to the wide inter-personal variations in commensal bacteria as well as fundamental differences between
probiotic strains. The further application of advanced omics technologies will provide an improved understanding
of the complex host-bacteria interactions, but research strategies must be well planned to provide informative
data that can be biologically interpreted. Once these biological mechanisms and physiological interactions can be
elucidated and more confidently defined, the translation of laboratory science to clinical treatments using probiotics
supplements will be substantially accelerated.
Albeit currently at an early stage, the future for probiotic research provides the exciting potential to influence
conditions related to both health and disease.
Future perspective
Although a wealth of literature on probiotic research is available, many of these relate to high-throughput analyses
of the gut microbiota that provide snapshots of the diversity at play in the microbiome, however this yields little
information about how this complex system interacts. Research efforts in the coming years are likely to focus on the
generation and combining of data from multiple omics platforms. This will allow in-depth characterization of the
microbiome through its genetic make-up and transcription products (metagenomics/metatranscriptomics), to its
proteins (metaproteomics) and metabolic products (metabolomics/metabonomics). Integrating these meta-omics
datasets to create a systems level framework that links the data through a comprehensive mechanistic model of
the microbiome will be one of the greatest future challenges of microbiome research [122]. However, through the
combination of these multiple technologies it will be possible to unlock the workings of this complex ecosystem
and understand which microbial components are functionally relevant. Once this is better understood then it
will be possible to harness individual strains for their specific health benefits with the ultimate aim of creating
Executive Summary
• Lots of research, but still no health claim: insufficient evidence from large-scale studies has led to the inability to
satisfy stringent regulations to legally associate a health claim to a probiotic supplement.
• Diversity, dysbiosis and strain specificity: The Human Microbiome Project has demonstrated the extensive
complexity in commensal bacteria residing within human hosts. This wide genetic diversity between probiotic
strains, coupled with the inter-personal variations in microbiome content, mean that the ability to define a
‘healthy’ or ‘dysbiotic’ microbiota is not without challenges that are dependent on the specific scenario being
investigated.
• Multi-omics technologies to revolutionize and accelerate microbiome science: advanced analytical technologies
have already begun to revolutionize the study of the microbiome, with individual omics technologies providing
insightful data in the workings and interactions of the microbiota. Improved connectivity of these technologies
will provide an increased ability to delineate the physiological and biochemical processes of host-bacteria
interactions to accelerate future potential for applications in health and disease.
• The biological basis and mechanisms of action of probiotics: with diverse biological functions and mechanisms
apparent across different bacterial strains, it is important for researchers and probiotic product developers to
understand the properties of each strain and apply these proactively to target a preferred physiological
interaction/response. For example, it is likely to be important and beneficial for probiotic strains that exhibit
anti-inflammatory properties to be applied to research in health conditions associated with an augmented
inflammatory response (e.g., Crohn’s disease).
• Clinical probiotic research: An early and consistent research focus on gastrointestinal diseases is now resulting in
inclusion of probiotics into evidence-based guidance for clinicians. Beyond the gut, the scope of clinical
conditions amenable to probiotic management seems almost limitless. However, although the results from
research in new indications, such as neurological pathologies, are very promising, a substantial amount of further
work is required to provide healthcare providers with the confidence to embrace probiotics into regular practice.
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individualized probiotic treatments for specific indications and diagnoses and apply these to robust RCTs for clinical
benefit.
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